m+Medelevator.RU
← Поиск публикаций
Research square · 2026

Impact of Alcohol Use Discontinuation on Adipose Tissue Insulin Resistance Among Latino Patients With and Without Underlying Chronic Liver Disease.

СтатьяПрепринтНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Patel Shyam, Do Albert, Shui Amy, Khalili Mandana

Аннотация

INTRODUCTION: We evaluated the effect of short-term moderate alcohol discontinuation on adipose tissue insulin resistance (adipo-IR) and factors associated with its change in Latinos with and without hepatitis C virus (HCV).

METHODS: Nondiabetic Latino adults without (N = 17) or with (N = 7) HCV underwent clinical, laboratory, genetic, and metabolic testing. Metabolic testing was repeated after 6.5 weeks of moderate alcohol discontinuation. Adipo-IR was measured using a 2-step insulin suppression test. Multivariable linear regression, including HCV status, identified factors associated with change in adipo-IR.

RESULTS: Median age was 50 years, 58% female, median BMI 26.3 kg/m2. Genetic ancestry was 57% European, 36% Native American, and 3.5% African. CYP2E1 genotyping showed 14% were homozygous for [c2/c2] risk-allele. No significant changes in adipo-IR occurred after alcohol discontinuation. On multivariable regression, CYP2E1 homozygous risk-allele (vs. none, estimate 0.25 mmol/L, p < 0.001) and overweight/obesity (vs. normal weight, estimate 0.13 mmol/L, p = 0.02), but not HCV, were associated with change in adipo-IR following alcohol discontinuation.

CONCLUSIONS: The effect of moderate alcohol cessation on adipo-IR is modulated by obesity and CYP2E1 homozygous risk-allele in Latinos, independent of HCV status. Alongside HCV eradication, alcohol cessation and weight loss are important for populations with CYP2E1 polymorphism to prevent adverse outcomes of insulin resistance.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты